Real-World CAR-T Delays in LBCL Drive Reliance on Bridging Therapy, According to Spherix Global Insights
Analysis of 187 audited patient charts reveals persistent operational barriers remain common for patients with large B-cell lymphoma (LBCL), reinforcing the role of targeted therapies during the CAR-T treatment journey EXTON, PA – May 21, 2026 – Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest […]
Sotyktu’s Psoriatic Arthritis Launch Builds Gradually in Month Two as Rheumatologists Continue to Take Measured Approach to TYK2 Adoption, According to Spherix Global Insights
Despite incremental gains in awareness and prescribing, most launch metrics continue to trail recent rheumatology benchmarks, underscoring both the challenges and strategic importance of the first TYK2 inhibitor launch in rheumatology. EXTON, PA – May 19, 2026 – Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest […]
SGLT2 Inhibitors Entrenched as Foundational CKD Therapy While GLP-1 Adoption Remains Selective, According to Spherix Global Insights
Nephrologists now prioritize SGLT2 inhibitors for kidney protection over glycemic control, while one-third report no perceived benefit of GLP-1s in CKD. Exton, PA – May 13, 2026 – Nephrologists are initiating SGLT2 inhibitors earlier in the chronic kidney disease (CKD) treatment journey and continuing them well below labeled eGFR thresholds. At the same time, real-world […]
Lupus Patients Continue to Navigate Delayed Diagnosis, High Disease Burden, and Complex Treatment Journeys, According to Spherix Global Insights
Despite expanding biologic use, nearly 60% of lupus patients report high disease activity, while rising costs and treatment complexity continue to drive switching and discontinuation. EXTON, PA, May 5, 2026 — New findings from Spherix Global Insights’ Patient Voice Dynamix™: Systemic Lupus Erythematosus (SLE) 2026 highlight a market still defined by high disease burden, fragmented […]
Spherix Advances Oncology Leadership with Novel PD-1 Findings and Inaugural Presence at American Society of Clinical Oncology (ASCO) Annual Meeting 2026
Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: EXTON, PA, April 29, 2026 — Spherix Global Insights continues to expand its presence in oncology market intelligence with the release of new findings from its RealTime Dynamix™ service focused on PD-1 inhibition in solid tumors, alongside the […]
Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment
High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a split in preferences EXTON, PA, April 24, 2026 — As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s LillyDirect in January 2024 and […]
SLE Market Evolution Accelerates as AstraZeneca’s Saphnelo SC Emerges as a Likely Key Challenger to GSK’s Benlysta
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients, increasing competitive switching, and a deep pipeline poised to further expand targeted treatment options. EXTON, PA — April 13, 2026 — The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among […]
Sickle Cell Care Reaches an Inflection Point as Gene Therapy Enthusiasm Rises, but Referral Pathways and Uptake Lag Due to Treatment Burden
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton, PA – March 10, 2026 – Spherix Global Insights today announced the release of its 2026 Patient Chart Dynamix™: Sickle Cell Disease (US) report, an in-depth analysis of 133 real-world patient charts collected from 86 U.S. hematologist/oncologists offering insight into current […]
FDA Approves Deucravacitinib (Sotyktu), First TYK2 Inhibitor for Psoriatic Arthritis
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials. he FDA approveddeucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), the company announced March 7, 2026.¹ The decision makes deucravacitinib the first oral TYK2 inhibitor approved for PsA — and […]
Spherix Global Insights Expands Advisory Capabilities with Launch of a New Market Access Suite of Services
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused on Market Access, expanding the company’s advisory capabilities to provide biopharma manufacturers and other stakeholders with comprehensive, data-driven insights across payer strategy, key account dynamics, organized customer engagement, and patient services optimization. This expansion represents a natural evolution […]